New York State Common Retirement Fund lowered its position in Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating) by 1.0% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 124,161 shares of the biotechnology company’s stock after selling 1,250 shares during the period. New York State Common Retirement Fund owned 0.17% of Axon Enterprise worth $17,101,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AXON. BlackRock Inc. lifted its holdings in Axon Enterprise by 6.2% in the 4th quarter. BlackRock Inc. now owns 7,366,629 shares of the biotechnology company’s stock valued at $1,156,559,000 after purchasing an additional 426,830 shares in the last quarter. Capital International Investors lifted its holdings in Axon Enterprise by 645.6% in the 4th quarter. Capital International Investors now owns 377,291 shares of the biotechnology company’s stock valued at $59,235,000 after purchasing an additional 326,691 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Axon Enterprise in the 4th quarter valued at $31,440,000. Alliancebernstein L.P. lifted its holdings in Axon Enterprise by 11.3% in the 4th quarter. Alliancebernstein L.P. now owns 1,477,546 shares of the biotechnology company’s stock valued at $231,975,000 after purchasing an additional 149,915 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. purchased a new position in Axon Enterprise in the 1st quarter valued at $12,825,000. Hedge funds and other institutional investors own 72.06% of the company’s stock.
Axon Enterprise Stock Performance
NASDAQ AXON opened at $116.60 on Friday. The company has a market cap of $8.28 billion, a P/E ratio of 224.24 and a beta of 0.66. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.43 and a quick ratio of 2.18. The stock has a 50-day moving average of $96.24 and a two-hundred day moving average of $113.38. Axon Enterprise, Inc. has a 1-year low of $82.49 and a 1-year high of $209.00.
Axon Enterprise (NASDAQ:AXON – Get Rating) last released its earnings results on Tuesday, May 10th. The biotechnology company reported $0.76 earnings per share for the quarter. The company had revenue of $256.43 million during the quarter, compared to the consensus estimate of $233.57 million. Axon Enterprise had a return on equity of 3.90% and a net margin of 4.62%. Axon Enterprise’s revenue was up 31.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.75) EPS. As a group, analysts anticipate that Axon Enterprise, Inc. will post 1.35 EPS for the current year.
Analysts Set New Price Targets
A number of brokerages have issued reports on AXON. JMP Securities reaffirmed a “buy” rating and issued a $195.00 target price on shares of Axon Enterprise in a research note on Wednesday, June 1st. Morgan Stanley downgraded Axon Enterprise from an “overweight” rating to an “equal weight” rating and set a $120.00 target price for the company. in a research note on Monday, May 23rd. StockNews.com raised Axon Enterprise from a “hold” rating to a “buy” rating in a research note on Saturday, June 18th. Robert W. Baird cut their target price on Axon Enterprise from $145.00 to $125.00 in a research note on Wednesday, May 11th. Finally, Northland Securities cut their price objective on Axon Enterprise from $180.00 to $130.00 in a research report on Thursday, May 12th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Axon Enterprise currently has an average rating of “Buy” and an average price target of $169.00.
In other news, Director Mark W. Kroll sold 3,159 shares of Axon Enterprise stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $102.82, for a total value of $324,808.38. Following the completion of the transaction, the director now owns 13,691 shares in the company, valued at approximately $1,407,708.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 6.90% of the company’s stock.
Axon Enterprise Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Receive News & Ratings for Axon Enterprise Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Axon Enterprise and related companies with MarketBeat.com’s FREE daily email newsletter.